AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6691639 — intervention group
Group type: COMPARATOR
Intervention: Control group intentions
Number of subjects: 12467
Study 31553108 — intervention group
Group type: EXPERIMENTAL
Intervention: Recontact letter emphasizing personal medical management implications
Number of subjects: 586
Study 31553108 — intervention group
Group type: EXPERIMENTAL
Intervention: Recontact letter emphasizing implications for family members
Number of subjects: 586
Study 31553108 — intervention group
Group type: EXPERIMENTAL
Intervention: Recontact letter emphasizing both personal and family implications
Number of subjects: 586
Study 31553108 — intervention group
Group type: COMPARATOR
Intervention: Control letter
Number of subjects: 586
Study 30357570 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world studies
Number of subjects: 0
Study 27015381 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk muscle stabilization exercise program (CO‐CUIDATE), conducted for 8 weeks, three times per week
Number of subjects: 46
Study 27015381 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 46
Study 24552894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing laparoscopic radical hysterectomy (NS-LRH)
Number of subjects: 96
Study 24552894 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic radical hysterectomy (LRH)
Number of subjects: 96
Study 22644797 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg axitinib Form IV FCIR tablets with food
Number of subjects: 48
Study 22644797 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg axitinib Form XLI FCIR tablets with high-fat, high-calorie meal
Number of subjects: 48
Study 22644797 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg axitinib Form XLI FCIR tablets with moderate-fat, standard-calorie meal
Number of subjects: 48
Study 22644797 — intervention group
Group type: COMPARATOR
Intervention: 5-mg axitinib Form IV FCIR tablets
Number of subjects: 48
Study 22644797 — intervention group
Group type: COMPARATOR
Intervention: 5-mg axitinib Form XLI FCIR tablets
Number of subjects: 48
Study 20196093 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including relationship-building, raffles, and screening survey administration
Number of subjects: 452
Study 20196093 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies including cash incentives, flexible scheduling, multiple reminders, chapter incentives, and use of chapter members as study personnel
Number of subjects: 452
Study 18848109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 60
Study 18848109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 60
Study 15747447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fludarabine
Number of subjects: 1447
Study 15747447 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine (CAP protocol or CHOP protocol)
Number of subjects: 1447
Study 11961622 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST‐VR training
Number of subjects: 29
Study 11961622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MIST‐VR training)
Number of subjects: 29
Study 9856715 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% isoflurane in oxygen and nitrogen
Number of subjects: 40
Study 9856715 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% isoflurane
Number of subjects: 40
Study 9856715 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7% sevoflurane
Number of subjects: 40
Study 9856715 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8% sevoflurane
Number of subjects: 40
Study 9856715 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 8548235 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative total parenteral nutrition (TPN)
Number of subjects: 203
Study 8548235 — intervention group
Group type: COMPARATOR
Intervention: Enteral feeding (Control)
Number of subjects: 203
Study 2794292 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict elimination diet of offending foods followed by double-blind, placebo-controlled food challenges.
Number of subjects: 23
Study 2794292 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges after 1 year or more of avoidance.
Number of subjects: 23
Study 401604 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine iodamide
Number of subjects: 78
Study 401604 — intervention group
Group type: COMPARATOR
Intervention: Renografin-60
Number of subjects: 78
Study 28452242 — intervention group
Group type: EXPERIMENTAL
Intervention: Homecare Aide Workforce Initiative (HAWI) graduates
Number of subjects: 0
Study 28452242 — intervention group
Group type: COMPARATOR
Intervention: Non-HAWI new hires
Number of subjects: 0
Study 28924473 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-only formulation (product A) applied for 90 s
Number of subjects: 25
Study 28924473 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine-alcohol combination (product B) applied for 180 s
Number of subjects: 25
Study 28924473 — intervention group
Group type: COMPARATOR
Intervention: Comparison of product A and product B
Number of subjects: 25
Study 26581140 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil/Leucovorin (FL)
Number of subjects: 142
Study 26581140 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/S-1 (IS)
Number of subjects: 142
Study 23483223 — intervention group
Group type: COMPARATOR
Intervention: H-FABP levels in SCI patients (paraplegia group: 18.5 ± 11.4 ng/ml; tetraplegia group: 16.3 ± 9.1 ng/ml)
Number of subjects: 56
Study 23483223 — intervention group
Group type: COMPARATOR
Intervention: H-FABP levels in complete SCI patients with lesions above T6 (24.21 ± 10.1 ng/ml)
Number of subjects: 56
Study 23483223 — intervention group
Group type: COMPARATOR
Intervention: H-FABP levels in SCI patients with metabolic syndrome (MetS) (25.8 ± 11.6 ng/ml)
Number of subjects: 56
Study 23483223 — intervention group
Group type: COMPARATOR
Intervention: H-FABP levels in SCI patients with duration < 12 months (14.8 ± 11.7 ng/ml)
Number of subjects: 56
Study 21093467 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g red pepper (RP)
Number of subjects: 25
Study 21093467 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred RP dose (1.8 ± 0.3 g/meal for spicy food users, 0.3 ± 0.1 g/meal for non-users)
Number of subjects: 25
Study 21093467 — intervention group
Group type: COMPARATOR
Intervention: No red pepper (RP)
Number of subjects: 25
Study 19179979 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg bolus, 500 mg/h infusion)
Number of subjects: 40
Study 19179979 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study 17331263 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on Prescription (EoP) - 16-week supervised training intervention and five counselling sessions
Number of subjects: 0
Study 17331263 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14968212 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenofemoral ligation (Group II, n=26)
Number of subjects: 36
Study 14968212 — intervention group
Group type: COMPARATOR
Intervention: Long saphenous stripping (Group I, n=10)
Number of subjects: 36
Study 11334299 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced (CE) SLINKY MR angiography
Number of subjects: 40
Study 11334299 — intervention group
Group type: EXPERIMENTAL
Intervention: MR DSA
Number of subjects: 40
Study 11334299 — intervention group
Group type: EXPERIMENTAL
Intervention: SLINKY MR angiography
Number of subjects: 40
Study 11334299 — intervention group
Group type: EXPERIMENTAL
Intervention: CE SLINKY MR angiography
Number of subjects: 40
Study 11334299 — intervention group
Group type: COMPARATOR
Intervention: Non-CE SLINKY MR angiography
Number of subjects: 40
Study 9298912 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable reinforced gowns
Number of subjects: 500
Study 9298912 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable single layer gowns
Number of subjects: 500
Study 9298912 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable cloth gowns
Number of subjects: 500
Study 9298912 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable gowns (general)
Number of subjects: 500
Study 8390232 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone replacement therapy (conjugated estrogen 1.25 mg/d and medroxyprogesterone acetate 10 mg/d for 10 days a month)
Number of subjects: 55
Study 8390232 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone replacement therapy
Number of subjects: 55
Study 8390232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 8390232 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout group (post-treatment follow-up)
Number of subjects: 55
Study 3731606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate
Number of subjects: 715
Study 3731606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715
Study 31203233 — intervention group
Group type: EXPERIMENTAL
Intervention: APOB, APOC3, and its subfractions (heparin precipitate, heparin‐soluble), ADLS‐defined Lp‐B
Number of subjects: 465
Study 31203233 — intervention group
Group type: EXPERIMENTAL
Intervention: APOC3 and its subfractions, Lp-B:C
Number of subjects: 465
Study 31203233 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA1, APOA2, APOE, or other ADLSs
Number of subjects: 465
Study 30401004 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) - 25 % (2622 (sd 204) kJ) of estimated energy requirements
Number of subjects: 14
Study 30401004 — intervention group
Group type: COMPARATOR
Intervention: Energy balance (EB) - 100 % (10 441 (sd 812) kJ) of estimated energy requirements
Number of subjects: 14
Study 26590124 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian Pi Li Qi (JPLQ) decoction treatment (group C)
Number of subjects: 150
Study 26590124 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (group B)
Number of subjects: 150
Study 26590124 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 150
Study 25219563 — intervention group
Group type: EXPERIMENTAL
Intervention: ProQuad® (MMRV) first dose
Number of subjects: 3112
Study 25219563 — intervention group
Group type: EXPERIMENTAL
Intervention: ProQuad® (MMRV) second dose
Number of subjects: 3112
Study 22395643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1203
Study 22395643 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 1203
Study 21142737 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device (combined light and heat energy)
Number of subjects: 63
Study 21142737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16730335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (8-week treatment)
Number of subjects: 101
Study 16730335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8-week treatment)
Number of subjects: 101
Study 16730335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6-month follow-up)
Number of subjects: 101
Study 16730335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (22-month follow-up)
Number of subjects: 101
Study 16226614 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 378
Study 16226614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 14646453 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal self-monitoring paradigm (reading single adjectives under various conditions)
Number of subjects: 20
Study 14646453 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal self-monitoring paradigm (reading aloud with acoustic distortion, alien feedback, and distorted alien feedback)
Number of subjects: 20
Study 11020749 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal S(+)-ketamine 1 mg/kg
Number of subjects: 42
Study 11020749 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular S(+)-ketamine 1 mg/kg
Number of subjects: 42
Study 11020749 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal S(+)-ketamine
Number of subjects: 42
Study 11020749 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular S(+)-ketamine
Number of subjects: 42
Study 8880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (unmonitored)
Number of subjects: 0
Study 8880596 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored, cautious, and selective approach to hyperventilation
Number of subjects: 0
Study 1580842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarsal rotation for minor trichiasis
Number of subjects: 384
Study 1580842 — intervention group
Group type: COMPARATOR
Intervention: Electrolysis for minor trichiasis
Number of subjects: 384
Study 1580842 — intervention group
Group type: COMPARATOR
Intervention: Cryoablation for minor trichiasis
Number of subjects: 384
Study 1580842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarsal rotation for major trichiasis
Number of subjects: 384
Study 1580842 — intervention group
Group type: COMPARATOR
Intervention: Tarsal advance and rotation for major trichiasis
Number of subjects: 384
Study 1580842 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for major trichiasis
Number of subjects: 384
Study 6421243 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: mitomycin C (MMC) + 5‐fluorouracil (5‐FU)
Number of subjects: 848
Study 6421243 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: MMC + 5‐FU + PSK or MMC + 5‐FU + OK‐432
Number of subjects: 848
Study 6421243 — intervention group
Group type: COMPARATOR
Intervention: Group C: surgery alone
Number of subjects: 848
Study 6421243 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant immunochemotherapy using OK‐432
Number of subjects: 848
Study 3549316 — intervention group
Group type: EXPERIMENTAL
Intervention: GP 47680 and GP 47779 (carbamazepine analogues)
Number of subjects: 24
Study 3549316 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 24
Study 31218418 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-field lymph node dissection (2F group)
Number of subjects: 31
Study 31218418 — intervention group
Group type: COMPARATOR
Intervention: Three-field lymph node dissection (3F group)
Number of subjects: 31
Study 29251456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide 1 hour a day
Number of subjects: 80
Study 29251456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide overnight
Number of subjects: 80
Study 29251456 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide 1 hour a day
Number of subjects: 80
Study 29251456 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide overnight
Number of subjects: 80
Study 26152626 — intervention group
Group type: EXPERIMENTAL
Intervention: Daycare laparoscopic cholecystectomy
Number of subjects: 62
Study 26152626 — intervention group
Group type: COMPARATOR
Intervention: Overnight stay laparoscopic cholecystectomy
Number of subjects: 62
Study 24461612 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg intravenously every 8 h
Number of subjects: 142
Study 24461612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) intravenously every 8 h
Number of subjects: 142
Study 24461612 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 142
Study 24461612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 21646549 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 0
Study 21646549 — intervention group
Group type: COMPARATOR
Intervention: Stereotype threat
Number of subjects: 0
Study 18363424 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy + pharmacotherapy
Number of subjects: 92
Study 18363424 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family psychoeducational group + pharmacotherapy
Number of subjects: 92
Study 18363424 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 92
Study 16931506 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal SMN1 gene copy numbers (one or three copies)
Number of subjects: 600
Study 16931506 — intervention group
Group type: COMPARATOR
Intervention: SMN2 gene copy numbers
Number of subjects: 600
Study 12760983 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (0.25 mmol/kg)
Number of subjects: 40
Study 12760983 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study 11061730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive geriatric rehabilitation (n=120)
Number of subjects: 243
Study 11061730 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=123)
Number of subjects: 243
Study 9177961 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day treatment with cefprozil
Number of subjects: 708
Study 9177961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-day treatment with cefprozil
Number of subjects: 708
Study 9177961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-day treatment with cefprozil (in patients with three or more previous episodes)
Number of subjects: 708
Study 9177961 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day treatment with cefprozil (in patients with three or more previous episodes)
Number of subjects: 708
Study 7505351 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AM) 5 mg, adjusted to 10 mg if necessary
Number of subjects: 32
Study 7505351 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (NTR) 10 mg, adjusted to 20 mg if necessary
Number of subjects: 32
Study 3100466 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol (10 mg/day)
Number of subjects: 10
Study 29108873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates (N = 14)
Number of subjects: 41
Study 29108873 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapeutic exercise (CTE) (N = 14)
Number of subjects: 41
Study 29108873 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 13)
Number of subjects: 41
Study 27026642 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of prednisone orally followed by 2 doses of intravenous hydrocortisone, each 8 hours apart
Number of subjects: 27
Study 27026642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 25049134 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin‐[9‐39] (Ex‐9) infusion (600‐750 pmol/kg/min)
Number of subjects: 8
Study 25049134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 8
Study 22554716 — intervention group
Group type: EXPERIMENTAL
Intervention: RP103 (delayed-release cysteamine bitartrate) taken every 12 hours
Number of subjects: 43
Study 22554716 — intervention group
Group type: COMPARATOR
Intervention: Cystagon (immediate-release cysteamine bitartrate) taken every 6 hours
Number of subjects: 43
Study 22554716 — intervention group
Group type: EXPERIMENTAL
Intervention: RP103 (delayed-release cysteamine bitartrate)
Number of subjects: 43
Study 22554716 — intervention group
Group type: COMPARATOR
Intervention: Cystagon (immediate-release cysteamine bitartrate)
Number of subjects: 43
Study 20636550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressing
Number of subjects: 281
Study 20636550 — intervention group
Group type: COMPARATOR
Intervention: Cadexomer iodine dressing
Number of subjects: 281
Study 18302069 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (three times a day from the first postoperative morning until oral intake)
Number of subjects: 18
Study 18302069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 18
Study 18302069 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing and Control group
Number of subjects: 18
Study 15986959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-based one-bottle adhesive system (Gluma Comfort Bond) applied to dry dentin (Group 1)
Number of subjects: 16
Study 15986959 — intervention group
Group type: COMPARATOR
Intervention: Acetone-based one-bottle adhesive system (Gluma One Bond) applied to dry dentin (Group 2)
Number of subjects: 16
Study 15986959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-based one-bottle adhesive system (Gluma Comfort Bond) applied to moist dentin (Group 3)
Number of subjects: 16
Study 15986959 — intervention group
Group type: COMPARATOR
Intervention: Acetone-based one-bottle adhesive system (Gluma One Bond) applied to moist dentin (Group 4)
Number of subjects: 16
Study 14970004 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) infusion
Number of subjects: 12
Study 10473874 — intervention group
Group type: EXPERIMENTAL
Intervention: GPIIb/IIIa inhibitors
Number of subjects: 20000
Study 7593106 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of a ruptured deltoid ligament
Number of subjects: 50
Study 7593106 — intervention group
Group type: COMPARATOR
Intervention: No repair of a ruptured deltoid ligament (control)
Number of subjects: 50
Study 2273204 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progesterone therapy
Number of subjects: 24
Study 2273204 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 7375871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg t.i.d. for 3 weeks
Number of subjects: 21
Study 7375871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg t.i.d. plus 100 mg suppository at night after 5-day placebo
Number of subjects: 21
Study 7375871 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of 50 mg indomethacin
Number of subjects: 21
Study 7375871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg q.i.d. for 8 days
Number of subjects: 21
Study 30004624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil infusion followed by remifentanil maintenance during the recovery phase (0.05 μg/kg/min)
Number of subjects: 80
Study 30004624 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative remifentanil infusion (0.2 μg/kg/min) discontinued upon surgery completion
Number of subjects: 80
Study 26869078 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-C total disc arthroplasty (TDA)
Number of subjects: 63
Study 26869078 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 63